Corvus Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Corvus Pharmaceuticals

25/03/2025 21:01

Corvus Pharmaceuticals Inc CRVS.OQ reported a quarterly adjusted loss of 18 cents​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of -14 cents.  The mean expectation of six analysts for the quarter was for a loss of 12 cents per share. Wall Street expected results to range from -13 cents to -10 cents per share.

Reported revenue was zero​; analysts expected zero.

Corvus Pharmaceuticals Inc's reported EPS for the quarter was a loss of 18 cents​.

The company reported a quarterly loss of $12.11 million.

Corvus Pharmaceuticals Inc shares had fallen by 20.6% this quarter.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 0.1% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The average consensus recommendation for the biotechnology & medical research peer group is  "buy."

Wall Street's median 12-month price target for Corvus Pharmaceuticals Inc is $13.00

This summary was machine generated from LSEG data March 25 at 09:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Dec. 31 2024
-0.12
-0.18
Missed
Sep. 30 2024
-0.12
-0.60
Missed
Jun. 30 2024
-0.11
-0.04
Beat
Mar. 31 2024
-0.12
-0.12
Met